{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:01:34Z","timestamp":1791284494579,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,16]],"date-time":"2025-02-16T00:00:00Z","timestamp":1739664000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004097","name":"Fondation ARC pour la Recherche sur le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004097","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.blre.2025.101272","type":"journal-article","created":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T16:09:27Z","timestamp":1739635767000},"page":"101272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["The landscape of immune monitoring in CAR-T cell therapy: A comprehensive review and survey study by the Cellular Therapy and Immunobiology Working Party of the EBMT"],"prefix":"10.1016","volume":"71","author":[{"given":"Simona","family":"Pagliuca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Malard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarl E.","family":"Mooyaart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Daskalakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovic","family":"Gabellier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Ram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Besley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edouard","family":"Forcade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladan","family":"Vucinic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda L\u00f3pez","family":"Corral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Vydra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"von Tresckow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Amat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Persis","family":"Amrolia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Vandenberghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich","family":"St\u00f6lzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Sica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Th\u00e9r\u00e8se","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorinde D.","family":"Hoogenboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valent\u00edn","family":"Ortiz-Maldonado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Kuball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Chabannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Ruggeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.blre.2025.101272_bb0005","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.blre.2025.101272_bb0010","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene Ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"32","key":"10.1016\/j.blre.2025.101272_bb0015","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.20.01467","article-title":"Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy","volume":"38","author":"Cappell","year":"2020","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.blre.2025.101272_bb0020","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"303","key":"10.1016\/j.blre.2025.101272_bb0025","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"issue":"18","key":"10.1016\/j.blre.2025.101272_bb0030","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.blre.2025.101272_bb0035","doi-asserted-by":"crossref","first-page":"e446","DOI":"10.1016\/S2352-3026(21)00057-0","article-title":"CAR T-cell therapy for multiple myeloma: state of the art and prospects","volume":"8","author":"van de Donk","year":"2021","journal-title":"Lancet Haematol"},{"issue":"12S","key":"10.1016\/j.blre.2025.101272_bb0040","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.bulcan.2021.04.008","article-title":"Immunomonitoring of patients treated with CAR-T cells for hematological malignancy: guidelines from the CARTi group and the francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)","volume":"108","author":"Rubio","year":"2021","journal-title":"Bull Cancer (Paris)"},{"issue":"12","key":"10.1016\/j.blre.2025.101272_bb0045","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.bulcan.2021.04.008","article-title":"Suivi immunologique des patients trait\u00e9s par cellules CAR-T pour h\u00e9mopathie maligne: recommandations du groupe CARTi et de la Soci\u00e9t\u00e9 francophone de greffe de moelle et de th\u00e9rapie cellulaire (SFGM-TC)","volume":"108","author":"Rubio","year":"2021","journal-title":"Bull Cancer (Paris)"},{"issue":"15","key":"10.1016\/j.blre.2025.101272_bb0050","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.1182\/bloodadvances.2022007057","article-title":"Real-world characteristics of T-cell apheresis and clinical response to tisagenlecleucel in B-cell lymphoma","volume":"6","author":"Cuffel","year":"2022","journal-title":"Blood Adv"},{"issue":"21","key":"10.1016\/j.blre.2025.101272_bb0055","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2025.101272_bb0060","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.658314","article-title":"Advanced flow cytometry assays for immune monitoring of CAR-T cell applications","volume":"12","author":"Blache","year":"2021","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.blre.2025.101272_bb0065","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/cyto.b.21941","article-title":"Monitoring CAR T-cells using flow cytometry","volume":"100","author":"Demaret","year":"2021","journal-title":"Cytometry B Clin Cytom"},{"issue":"1","key":"10.1016\/j.blre.2025.101272_bb0070","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.blre.2025.101272_bb0075","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s15010-020-01521-5","article-title":"Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper","volume":"49","author":"Los-Arcos","year":"2021","journal-title":"Infection"},{"issue":"3","key":"10.1016\/j.blre.2025.101272_bb0080","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"11","key":"10.1016\/j.blre.2025.101272_bb0085","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1182\/bloodadvances.2021004604","article-title":"Blueprint for the discovery of biomarkers of toxicity and efficacy for CAR T cells and T-cell engagers","volume":"5","author":"Paczesny","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.blre.2025.101272_bb0090","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1182\/hematology.2023000472","article-title":"Recognizing, defining, and managing CAR-T hematologic toxicities","volume":"2023","author":"Rejeski","year":"2023","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"8","key":"10.1016\/j.blre.2025.101272_bb0095","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/bloodadvances.2023011767","article-title":"Applying the EHA\/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality","volume":"8","author":"Rejeski","year":"2024","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.blre.2025.101272_bb0100","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000889","article-title":"An international survey on grading, diagnosis, and Management of Immune Effector Cell-Associated Hematotoxicity (ICAHT) following CAR T-cell therapy on behalf of the EBMT and EHA","volume":"7","author":"Rejeski","year":"2023","journal-title":"HemaSphere"},{"issue":"5","key":"10.1016\/j.blre.2025.101272_bb0105","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI125423","article-title":"CD19 CAR T cell product and disease attributes predict leukemia remission durability","volume":"129","author":"Finney","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2025.101272_bb0110","series-title":"Immune Monitoring","author":"Berger","year":"2022"},{"issue":"21","key":"10.1016\/j.blre.2025.101272_bb0115","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2017-06-786129","article-title":"Cellular kinetics of CTL019 in relapsed\/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia","volume":"130","author":"Mueller","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2025.101272_bb0120","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.blre.2025.101272_bb0125","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1182\/bloodadvances.2020004038","article-title":"Absolute lymphocyte count proliferation kinetics after CAR T-cell infusion impact response and relapse","volume":"5","author":"Faude","year":"2021","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.blre.2025.101272_bb0130","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1182\/bloodadvances.2020003959","article-title":"Axicabtagene ciloleucel in vivo expansion and treatment outcome in aggressive B-cell lymphoma in a real-world setting","volume":"5","author":"Ayuk","year":"2021","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.blre.2025.101272_bb0135","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3324\/haematol.2022.281110","article-title":"Molecular monitoring of T-cell kinetics and migration in severe neurotoxicity after real-world CD19-specific chimeric antigen receptor T cell therapy","volume":"108","author":"Berger","year":"2022","journal-title":"Haematologica"},{"issue":"27","key":"10.1016\/j.blre.2025.101272_bb0140","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.19.02103","article-title":"Axicabtagene Ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity","volume":"38","author":"Jacobson","year":"2020","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.blre.2025.101272_bb0145","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.blre.2025.101272_bb0150","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41467-019-13880-1","article-title":"Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy","volume":"11","author":"Sheih","year":"2020","journal-title":"Nat Commun"},{"issue":"24","key":"10.1016\/j.blre.2025.101272_bb0155","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1182\/blood.2024024381","article-title":"Baseline immune state and T-cell clonal kinetics are associated with durable response to CAR-T therapy in large B-cell lymphoma","volume":"144","author":"Maurer","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2025.101272_bb0160","doi-asserted-by":"crossref","first-page":"7156","DOI":"10.1182\/blood-2023-190332","article-title":"Detection of CAR-T cell persistence with digital droplet PCR: correlation of in vivo expansion with clinical outcomes in a cohort of B-cell lymphoma patients","volume":"142","author":"Cassanello","year":"2023","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2025.101272_bb0165","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1182\/bloodadvances.2024013146","article-title":"CAR T-cell expansion: harmful or helpful?","volume":"8","author":"Lionel","year":"2024","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2025.101272_bb0170","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1182\/blood-2021-152309","article-title":"Tisagenlecleucel and Axicabtagene Ciloleucel expansion kinetics and CAR T cell attributes in the infusion products are early predictors of clinical efficacy","volume":"138","author":"Carniti","year":"2021","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2025.101272_bb0175","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"issue":"7709","key":"10.1016\/j.blre.2025.101272_bb0180","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","article-title":"Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells","volume":"558","author":"Fraietta","year":"2018","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.blre.2025.101272_bb0185","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1172\/JCI130144","article-title":"CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration","volume":"130","author":"Nobles","year":"2019","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.blre.2025.101272_bb0190","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/cyto.b.21891","article-title":"Monitoring CAR-T cell kinetics in clinical trials by multiparametric flow cytometry: benefits and challenges","volume":"100","author":"Sarikonda","year":"2021","journal-title":"Cytometry B Clin Cytom"},{"issue":"7897","key":"10.1016\/j.blre.2025.101272_bb0195","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4+ CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.blre.2025.101272_bb0200","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1038\/s41409-018-0167-8","article-title":"Immune monitoring in allogeneic hematopoietic stem cell transplant recipients: a survey from the EBMT-CTIWP","volume":"53","author":"Greco","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2025.101272_bb0205","doi-asserted-by":"crossref","unstructured":"Murphy MK, Black NA, Lamping DL, et al. Consensus development methods, and their use in clinical guideline development. Health Technol Assess (Winch Eng) 1998;2(3):i\u2013iv, 1\u201388.","DOI":"10.3310\/hta2030"},{"issue":"25","key":"10.1016\/j.blre.2025.101272_bb0210","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1200\/JCO.2012.42.0489","article-title":"American Society of Clinical Oncology Clinical Practice Guidelines: Formal Systematic Review\u2013Based Consensus Methodology","volume":"30","author":"Loblaw","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.blre.2025.101272_bb0215","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41409-023-01958-w","article-title":"Practice harmonization workshops of EBMT: an expert-based approach to generate practical and contemporary guidelines within the arena of hematopoietic cell transplantation and cellular therapy","volume":"58","author":"Yakoub-Agha","year":"2023","journal-title":"Bone Marrow Transplant"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25000177?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25000177?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T18:06:49Z","timestamp":1762279609000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X25000177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":43,"alternative-id":["S0268960X25000177"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2025.101272","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The landscape of immune monitoring in CAR-T cell therapy: A comprehensive review and survey study by the Cellular Therapy and Immunobiology Working Party of the EBMT","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2025.101272","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101272"}}